WESTBURY, N.Y.--(BUSINESS WIRE)--BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today launched LEUKOMAX XL, a new leukopak product that provides researchers with a minimum of 15 billion TNC. LEUKOMAX XL features the most cells from a single donor collection per volume, including over 50% more cells per bag than the standard Leukopak Full Paks, and is available through U.S.

纽约州韦斯特伯里（商业新闻短讯）--全球研究合作伙伴和药物和诊断开发生物样本解决方案提供商BioIVT今天推出了LEUKOMAX XL，这是一种新的leukopak产品，为研究人员提供至少150亿TNC。LEUKOMAX XL具有每体积单个供体收集的最多细胞，每袋细胞比标准的Leukopak Full PAK多50%以上，可通过美国获得。

and U.K. collection sites..

和英国收集网站。。

“BioIVT is proud to provide direct access to fresh, donor-derived, standard and mobilized paks, including our new LEUKOMAX XL option, to support the development of advanced cell and gene therapies (CGT),” said Dr. Parijat Jain, Vice President, CGT at BioIVT. “There’s a lot of immediate benefit to this product because of the large cell count – it saves extensive time and resources for developers and enables them to get more cells at once without needing to purchase additional leukopaks, which helps prevent delays, reduces cost and eventually delivers considerable value for CGT development.”.

BioIVT的CGT副总裁Parijat Jain博士说：“BioIVT很自豪能够直接获得新鲜的，供体来源的，标准的和动员的PAK，包括我们新的LEUKOMAX XL选项，以支持先进细胞和基因疗法（CGT）的发展。”。“由于细胞数量大，该产品有很多直接的好处-它为开发人员节省了大量的时间和资源，使他们能够在不需要购买额外的白细胞的情况下一次获得更多的细胞，这有助于防止延迟，降低成本，并最终为CGT开发带来可观的价值。”。

With blood disorders and autoimmune diseases on the rise, new advancements in leukapheresis and an increased demand for more personalized medicine, the industry is seeing market demand for high-quality cellular starting material such as leukopaks. With its new LEUKOMAX XL offering, BioIVT has expanded its capacity and capability support for cell & gene therapy research globally, now and into the future..

随着血液疾病和自身免疫性疾病的增加，白细胞分离术的新进展以及对更多个性化药物的需求增加，该行业正在看到对高质量细胞起始材料（如白细胞）的市场需求。随着其新的LEUKOMAX XL产品的推出，BioIVT现在和将来都扩大了其在全球细胞和基因治疗研究中的能力和能力支持。。

The company has more than 35 years of experience in biospecimen procurement to bring the best products to researchers in need, including its diverse donor pool consisting of over 600 recallable consented donors in the U.S. and U.K. All products are collected using strict IRB protocols at strategically located facilities under FDA and HTA guidelines..

该公司在生物样本采购方面拥有超过35年的经验，可以为需要的研究人员提供最好的产品，包括其多样化的捐赠者库，其中包括美国和英国的600多名可重新获得同意的捐赠者。根据FDA和HTA指南，所有产品都是在战略位置的设施中使用严格的IRB协议收集的。。

About BioIVT

关于BioIVT

BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. We specialize in control and disease state samples including human and animal tissues or preparations, ADME products and research services, cell and gene therapy products, blood, and other biofluids.

BioIVT通过向生命科学和诊断行业提供高质量的个性化生物样本解决方案和研究服务，实现了更智能的科学，加速了医学突破。我们专注于控制和疾病状态样本，包括人类和动物组织或制剂，ADME产品和研究服务，细胞和基因治疗产品，血液和其他生物流体。

Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.

我们无与伦比的临床标本组合直接支持精准医学研究，并通过将综合临床数据与供体样本相结合来改善患者预后。通过结合我们的技术专长、卓越的客户服务以及无与伦比的生物标本获取，BioIVT在提升SCIENCE®方面成为研究界值得信赖的合作伙伴。